A new frontier in epilepsy: Novel antiepileptogenic drugs

Journal of Pharmacological Sciences

Volumn 100, Issue 5, 2006, Pages 487-494

  Sasa, Masashi ^a,b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Nagisa Hospital   (Japan)

Author keywords

Antiepileptic drugs; Epilepsy; Epileptogenesis; Ictogenesis; Levetiracetam

Indexed keywords

ANTICONVULSIVE AGENT; BRAIN DERIVED GROWTH FACTOR; CARBAMAZEPINE; DIAZEPAM; ETIRACETAM; NERVE CELL ADHESION MOLECULE; NERVE GROWTH FACTOR; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; DRUG DERIVATIVE; PIRACETAM;

BRAIN; BRAIN INJURY; CLINICAL TRIAL; COGNITION; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; EPILEPSY; EPILEPTIC FOCUS; EPILEPTOGENESIS; GLIOSIS; HISTOLOGY; HUMAN; MENTAL FUNCTION; META ANALYSIS; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; REVIEW; SEIZURE; SYSTEMATIC REVIEW; ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; PATHOPHYSIOLOGY; RAT;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; EPILEPSY; MODELS, BIOLOGICAL; PIRACETAM; RATS;

EID: 33747612918     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.CPJ06010X     Document Type: Review

References (62)

1. Löcsher W. Animal models of intractable epilepsy. Prog Neurobiol. 1997;53:239-258.
2. Temkin NR, Jarell AD, Anderson GD. Antiepileptogenic agents: How close are we? Drugs. 2001;61:1045-1055.
3. Weaver DF. Epileptogenesis, ictogenesis and the design of future antiepileptic drugs. Can J Neurol Sci. 2003;30:4-7.
4. Löscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci. 2002;23:113-118.
5. Pitman A, Sutula TP. Is epilepsy a progressive disorder? Process for new therapeutic approaches in temporal lobe epilepsy. Lancet Neurol. 2002;1:173-181.
6. Carvazos JE, Das I, Sutula TP. Neuronal loss induced by kindling in limbic pathways by kindling : evidence for induction of hippocampal sclerosis by repeated brief seizures. J Neurosci. 1994;14:3106-3121.
7. Scott BW, Wang S, Burnham WM, De Boni U, Wojtowicz JM. Kindling-induced neurogenesis in the dendate gyrus of the rat. Neurosci Lett. 1998;248:73-76.
8. Cavazos JE, Golarai G, Sutula TP. Mossy fibre synaptic reorganization induced by kindling: time course of development, progression, and permanence. J Neurosci. 1991;11:2795-2803.
9. Represa A, Salle GL, Ben-Ari Y. Hippocampal plasticity in the kindling model of epilepsy in rats. Neurosci Lett. 1989;99:345-350.
10. Hansen A, Jorgensen OS, Bolwig TG, Barry DI. Hippocampal kindling alters the concentration of glial fibrillary acidic protein and other marker proteins in rat brain. Brain Res. 1990;531:307-311.
11. Khurgel M, Racine RJ, Ivy GO. Kindling causes changes in the composition of the astrocytic skeleton. Brain Res. 1992;592:338-342.
12. Hughes PE, Alexi T, Walton M. Activity and injury-dependent expression of inducible transcription factors, growth factors and apotosis related genes within the central nervous system. Prog Neurobiol. 1999;57:421-450.
13. Knipper M, Leung LS, Zhao D, Rylett RJ. Short-term modulation of glutamatergic in adult rat hippocampus by NGF. Neuroreport. 1994;5:2433-2436.
14. Yilmazer-Hanke DM, Wolf HK, ScgeammJ, Elger CE, Wiestler OD, Blumcke I. Subregional pathology of the amygdale complex and entorhinal region in surgical specimen from patients with pharmacoresistant temporal lobe epilepsy. J Neuropathol Exp Neurol. 2000;59:907-920.
15. Henshall DC, Clark RSB, Adelson PD, Chen M, Watkins SC, Simon RP. Alterations in bcl-2 and caspase gene family protein expression in human temporal epilepsy. Neurology. 2000;55:250-257.
16. Rabinowicz AL, Correale J, Boutros RB, Couldwell WT, Henderson CW, DeGiorgio CM. Neuon-specific enolase is increased after single seizures during inpatient video/EEG monitoring. Epilepsia. 1996;37:122-125.
17. Steinhoff BJ, Tumani H, Otto M. Cisternal S100 protein and neuron-specific enolase are elevated and ste-specific markers in intractable temporal lobe epilepsy. Epilepsy Res. 1999;36:75-82.
18. Mikkonen M, Soininen H, Kalviainen R. Remodeling of neuronal circuitries in human temporal epilepsy; increased expression of highly polysialylated neural cell adhesion molecule in the hippocampus and the entorhinal cortex. Ann Neurol. 1998;44:923-934.
19. Pitkanen A, Halonen T. Prevention of epilepsy. Trends Pharmacol Sci. 1998;19:253-255.
20. Silver JM, Shin C, McNamara JO. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy. Ann Neurol. 1991;29:356-363.
21. Löscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res. 2002;50:105-123.
22. Amano K, Hamada K, Yagi K, Seino M. Antiepileptic effects of topiramate on amygdaloid kindling in rats. Epilepsy Res. 1998;31:123-128.
23. Bolanos AR, Sarkisian M, Yang Y, Hori A, Helmers SL, Mikati M, et al. Comparison of valproate and phenobarbital treatment after status epilepticus in rats. Neurology. 1998;51:41-48.
24. Klitgaard HV, Matagne AC, Vanneste-Goemaere J, Margineanu DG. Effects of prolonged administration of levetiracetam on pilocarpine-induced epileptogenesis in rat. Epilepsia. 2001;42 Suppl 7:114-115.
25. Beghi E. Overview of studies to prevent posttraumatic epilepsy. Epilepsia. 2003;44 Suppl 10:21-26.
26. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia. 2001;42 Suppl 4:13-18.
27. Margineanu DG, Klitgaard H. Levetiracetam: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors. Antiepileptic drugs. 5th ed. Lippincott Williams & Wilkins; 2002. p. 419-427.
28. Klitgaard H, Matagne A, Gobert J, Wulfert J. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol. 1998;353:191-206.
29. Löscher W, Hönack D. Profile of ucb L059, a novel anti-convulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol. 1993;232:147-158.
30. Gower A, Hirsch E, Boehrer A, Noyer M, Marescanx C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 1995;22:207-213.
31. Glien M, Brandt C, Potschka H, Löscher W. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia. 2002;43:350-357.
32. Sasa M, Yan HD, Ishihara K, Nagayama T, Serikawa T. Is levetiracetam distinct from conventional antiepileptic drugs in antiepileptogenic properties in spontaneous epileptic rats? Epilepsia. 2005;46 Suppl 1:94-95.
33. 2+ currents. Seizure. 2001;10:279-286.
34. Sills GJ, Leach JP, Fraser CM, Forrest G, Patsalos PN, Brodie MJ. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. Eur J Pharmacol. 1997;325:35-40.
35. Fraser CM, Sills GJ, Butler E, Thompson GC, Lindsay K, Duncan R, et al. Effects of valproate, vigabatrin and tiagabin on GABA uptake into human astrocytes cultured from foetal and adult brain tissue. Epilptic Disord. 1999;1:153-157.
36. Tong X, Patsalos PN. A microdialysis study of the novel anti-epileptic drug levetiracetam: extracellular pharmacokinetics and effect of taurine in rat brain. Br J Pharmacol. 2001;133:867-874.
37. Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA-and glycine-gated currents. Br J Pharmacol. 2002;136:659-672.
38. Margineanu DG, Klitgaard H. Levetiracetam has no significant gamma-aminobutyric acid-related effect on paired-pulse interaction in the dentate gyrus of rats. Eur J Pharmacol. 2003;466:255-261.
39. 2+ current in pyramidal neurones of rat hippocampal slices. Neurosci Lett. 2001;306:5-8.
40. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43:9-18.
41. Margineanu DG, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res. 2000;42:281-285.
42. Fuks B, Gillard M, Michel P, Lynch B, Vertongen P, Leprince P, et al. Localization and photoaffinity labeling of the levetiracetam binding site in rat brain and certain cell lines. Eur J Pharmacol. 2003;478:11-19.
43. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101:9861-9866.
44. 3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur J Pharmacol. 2003;478:1-9.
45. Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci U S A. 1999;96:15268-15273.
46. Löscher W, Hönack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther. 1998;284:474-479.
47. Stratton SC, Large CH, Cox B, Davies G, Hagan RM. Effects of lamotorigine and levetiracetam on seizure development in a rat amygdala kindling model. Epilepsy Res. 2003;53:95-106.
48. Serikawa T, Yamada J. Epileptic seizures in rats homozygous for two mutations, zitter and tremor. J Hered. 1986;77:441-444.
49. Serikawa T, Yamada J, Ujihara H, Ohno Y, Sasa M, Takaori S. Ontogeny of absence-like and tonic seizures in the spontaneously epileptic rat. Laboratory Animals. 1991;25:216-221.
50. Sasa M, Ohno Y, Ujihara H, Fujita Y, Yoshimura M, Takaori S, et al. Effects of antiepileptic drugs on absence-like and tonic seizures in the spontaneously epileptic rat, a double mutant rat. Epilepsia. 1988;29:505-513.
51. Kitada K, Akimitsu T, Shigematsu Y, Kondo A, Maihara T, Yokoi N, et al. Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system. J Neurochem. 2000;74:2512-2519.
52. Kuramoto T, Kitada K, Inui T, Sasaki Y, Ito K, Hase T, et al. Attractin/mahogany/zitter plays a critical role in myelination of the central nervous system. Proc Natl Acad Sci U S A. 2001;98:559-564.
53. Amano H, Amano T, Matsubayashi H, Ishihara K, Serikawa T, Sasa M. Enhanced calcium influx in hippocampal CA3 neurons of spontaneously epileptic rats. Epilepsia. 2001;42:345-350.
54. Momiyama T, Ishihara K, Serikawa T, Moritake K, Sasa M. Effects of nicardipine on abnormal excitability of CA3 pyramidal cells in hippocampal slices of spontaneously epileptic rats. Eur J Pharmacol. 1995;280:119-123.
55. Ishihara K, Sasa M, Momiyama T, Ujihara H, Nakamura J, Serikawa T, et al. Abnormal excitability of hippocampal CA3 pyramidal neurons of spontaneously epileptic rats (SER), a double mutant. Exp Neurol. 1993;119:287-290.
56. Yan H-D, Ishihara K, Serikawa T, Sasa M. Activation by N-acetyl-L-aspartate of acutely dissociated hippocampal neurons in rats via metabotropic glutamate receptors. Epilepsia. 2003;44:1153-1159.
57. Cai Ji-qun, Ishihara K, Nagayama T, Serikawa T, Sasa M. Long-lasting anti-epileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional anti-epileptic drugs. Epilepsia. 2005;46:1362-1370.
58. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85:77-85.
59. Yan D-H, Cai Ji-qun, Ishihara K, Nagayama T, Serikawa T, Sasa M. Separation of anti-epileptogenic and anti-seizure effects of levetiracetam in the spontaneously epileptic rat (SER). Epilepsia. 2005;46:1170-1177.
60. Dedeurwaerdere S, Boon P, De Smedt T, Claeys P, Raedt R, Bosman T, et al. Chronic levetiracetam treatment early in life decreases epileptiform events in young GAERS, but does not prevent the expression of spike and wave discharges during adulthood. Seizure. 2005;14:403-411.
61. Husum H, Bolwig TG, Sanchez C, Mathe AA, Hansen SL. Levetiracetam prevents changes in levels of brain-derived neurotropic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdale kindling: implications for antiepileptogenic and mood-stabilizing properties. Epilepsy Behav. 2004;5:204-215.
62. Gu J, Lynch BA, Anderson D. The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats. Eur J Neurosci. 2004;19:334-345.